Clinical trial
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With…
NCT00418665 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00418665 |
|---|---|
| Title | A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid |
| Official title | A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide. |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes, Thrombocytopenia |
| Intervention type | Biological, Drug |
| Interventions | AMG 531, Placebo |
| Enrollment | 39 |
| Start date | Dec 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Oct 1, 2010 |
| First posted | Jan 5, 2007 |
| Last update posted | Jan 24, 2011 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: